Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Beyond basal laminar drusen: expanded retinal phenotypes in membranoproliferative glomerulonephritis
Author Affiliations & Notes
  • Claudia Liang-Peng
    Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Abraham Olvera-Barrios
    Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Roy Schwartz
    Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Gabriela Grimaldi
    Ophthalmology, Neurocentro - Istituto di Neuroscienze Cliniche della Svizzera Italiana, Lugano, Ticino, Switzerland
  • Catherine A Egan
    Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Adnan Tufail
    Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Claudia Liang-Peng None; Abraham Olvera-Barrios None; Roy Schwartz None; Gabriela Grimaldi None; Catherine Egan Heidelberg Engineering, Inozyme Pharma, Code C (Consultant/Contractor); Adnan Tufail Allergan, Allegro, Adverum, Annexon, Apellis, Bayer, Genetech, Heidelberg Engineering, Iveric Bio, Kanghong Pharmaceuticals, Kodiak Sciences, Novartis, Oxurion, Roche, Code C (Consultant/Contractor), Bayer, Novartis, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6669. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Claudia Liang-Peng, Abraham Olvera-Barrios, Roy Schwartz, Gabriela Grimaldi, Catherine A Egan, Adnan Tufail; Beyond basal laminar drusen: expanded retinal phenotypes in membranoproliferative glomerulonephritis. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6669.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe various retinal manifestations of a rare, complement-driven disease known as membranoproliferative glomerulonephritis.

Methods : Retrospective single-center observational case series of patients with ocular pathology and renal biopsy-confirmed membranoproliferative glomerulonephritis, seen between 2006-2023. Multimodal imaging and electronic health records were reviewed for demographic parameters and disease course, including any changes in visual acuity or ocular pathology.

Results : A total of 6 patients (12 eyes) with a mean age at presentation of 32.8 (SD = 14) years and a mean follow-up of 4.5 years were included in the study. Visual acuity remained unchanged in 67% of the patients, and all patients remained with vision better than 6/12 by the end of follow-up. All patients presented with bilateral drusen at initial visit, primarily in the temporal or macular regions. Fundus autofluorescence revealed these to be hyperfluorescent. Pigmentary changes were observed in 4/12 eyes, with 2/12 eyes having over 12 years of follow up and demonstrable development and progression of retinal pigment epithelium atrophy without foveal involvement. Additionally, optical coherence tomography revealed vertical hyperreflective lesions/outer retinal columnar abnormalities (ORCA), as well as cystoid macular edema in 2 eyes.

Conclusions : Basal laminar drusen were seen bilaterally in both type I and type II membranoproliferative glomerulonephritis. Yet it is of interest to observe the phenotypic variation in this rare complement-driven disease, with additional findings such as outer retinal columnar abnormalities (ORCA), cystoid macular edema and progressive retinal pigment epithelium atrophy that may be seen in longitudinal follow-up. Future studies genotyping the patient cohort would be of interest to understand any underlying molecular mechanisms.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×